Cargando…

Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review

The safety profile of hydroxyurea (HU) in patients with sickle-cell disease (SCD) is relatively well known. However, despite the suspected association of HU with myeloid neoplasms in myeloproliferative neoplasms (MPN), and the publication of sporadic reports of myeloid malignancies in SCD patients t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flevari, Pagona, Voskaridou, Ersi, Galactéros, Frédéric, Cannas, Giovanna, Loko, Gylna, Joseph, Laure, Bartolucci, Pablo, Gellen-Dautremer, Justine, Bernit, Emmanuelle, Charneau, Corine, Habibi, Anoosha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775156/ https://www.ncbi.nlm.nih.gov/pubmed/36551957 http://dx.doi.org/10.3390/biomedicines10123201

Ejemplares similares

Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study
por: Habibi, Anoosha, et al.
Publicado: (2023)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen
por: Paule, Ines, et al.
Publicado: (2011)

Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea
por: Rakotoson, Marie Georgine, et al.
Publicado: (2015)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

How to implement endurance exercise training in sickle cell disease
por: Messonnier, Laurent A., et al.
Publicado: (2020)

First evidence of subclinical renal tubular injury during sickle-cell crisis
por: Audard, Vincent, et al.
Publicado: (2014)

Sickle cell disease patients with COVID‐19 in Guadeloupe: Surprisingly favorable outcomes
por: Bernit, Emmanuelle, et al.
Publicado: (2022)

P111: COVID-19 IN PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE: A SINGLE CENTER EXPERIENCE
por: Dimopoulou, M, et al.
Publicado: (2022)

Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients
por: Elenga, Narcisse, et al.
Publicado: (2022)

Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis
por: Lopinto, Julien, et al.
Publicado: (2022)

PB2505: THERAPEUTIC PHLEBOTOMY INSTANTLY AFFECTS BLOOD PARAMETERS AND VISCOCITY IN SICKLE CELL DISEASE PATIENTS
por: Jebali, Amna, et al.
Publicado: (2023)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Environmental Influences on Daily Emergency Admissions in Sickle-Cell Disease Patients
por: Mekontso Dessap, Armand, et al.
Publicado: (2014)

Detection of the sickle hemoglobin allele using a surface plasmon resonance based biosensor
por: Breveglieri, Giulia, et al.
Publicado: (2019)

Score Predicting Acute Chest Syndrome During Vaso-occlusive Crises in Adult Sickle-cell Disease Patients
por: Bartolucci, Pablo, et al.
Publicado: (2016)

Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a Patient with Sickle Cell Anemia
por: Baz, Walid, et al.
Publicado: (2012)

Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal
por: Thein, Swee Lay, et al.
Publicado: (2020)

Positron Emission Tomography With (18)F-Fluorodeoxyglucose in Patients With Sickle Cell Acute Chest Syndrome
por: de Prost, Nicolas, et al.
Publicado: (2015)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Characteristics of Moyamoya Syndrome in Sickle-Cell Disease by Magnetic Resonance Angiography: An Adult-Cohort Study
por: Kauv, Paul, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Sickle cell disease induces resistance to cutaneous carcinogenesis
por: Soutou, Boutros, et al.
Publicado: (2020)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers
por: Alkobtawi, Mansour, et al.
Publicado: (2022)

Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database
por: Leleu, Henri, et al.
Publicado: (2021)

Development of a High-Resolution Melting Approach for Scanning Beta Globin Gene Point Mutations in the Greek and Other Mediterranean Populations
por: Chassanidis, Christos, et al.
Publicado: (2016)

Novel Therapeutic Advances in β-Thalassemia
por: Makis, Alexandros, et al.
Publicado: (2021)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ijb8q3f7sqhma71cnfn0sl5job